natgillin/translations-raw huggingface dataset:
An immunogenic composition or vaccine consisting essentially of a VZV gE antigen truncated to remove the carboxy terminal anchor region, wherein the gE truncate is not in the form of a fusion protein and consists of the amino acid sequence of SEQ ID NO:1, in combination with an adjuvant comprising QS21, 3D MPL and liposomes comprising cholesterol. 
Antigen VZV gE, skraćen kako bi se uklonilo C-terminalno sidrišno područje i koji nije u obliku fuzijskog proteina, namijenjen upotrebi u sprječavanju ili ublažavanju zone i/ili postherpetične neuralgije, naznačen time što antigen VZV gE treba primijeniti u kombinaciji s adjuvansom TH-1, koji sadrži QS21 i 3D MPL.
The dosage form for use according to claim 1, wherein said solid solution or solid dispersion comprises at least one pharmaceutically acceptable water-soluble polymer selected from the group consisting of homopolymer of N-vinyl lactam, copolymer of N-vinyl lactam, cellulose ester, cellulose ether, high molecular polyalkylene oxide, polyacrylate, polymethacrylate, polyacrylamide, polyvinyl alcohol, vinyl acetate polymer, oligosaccharide, and polysaccharide, and wherein said solid solution or solid dispersion comprises at least one pharmaceutically acceptable surfactant having an HLB value of from 4 to 10 selected from the group consisting of polyoxyethylene alkyl ether, polyoxyethylene alkylaryl ether, polyethylene glycol fatty acid ester, alkylene glycol fatty acid mono ester, sucrose fatty acid ester, and sorbitan fatty acid mono ester. 
Oblik doziranja za uporabu prema zahtjevu 1, naznačen time da navedena otopina krutih tvari ili navedena disperzija krutih tvari sadrži barem jedan farmaceutski prihvatljiv polimer koji je topljiv u vodi odabran iz skupine koja sadrži homopolimer N-vinil laktama, kopolimer N-vinil laktama, celuloza ester, celuloza eter, visoko molekularni polialkilen oksid, poliakrilat, polimetakrilat, poliakrilamid, polivinil alkohol, vinil acetat polimer, oligosaharid, te polisaharid, te pri čemu navedena kruta otopina ili kruta disperzija sadrži barem jedan farmaceutski prihvatljiv surfaktant koji ima HLB vrijednost od 4 do 10 odabran iz skupine koja sadrži polioksietilen alkil eter, polioksietilen alkilaril eter, polietilen glikol ester masne kiseline, alkilen glikol mono ester masne kiseline, saharoza ester masne kiseline, te sorbitan mono ester masne kiseline.
An immunogenic composition or vaccine comprising a Varicella-Zoster virus (VZV) glycoprotein E (gE) antigen truncated to remove the C-terminal anchor region, wherein the VZV gE truncate is not in the form of a fusion protein, in combination with a TH-1 adjuvant comprising QS21 and 3D MPL, for use in the prevention or amelioration of shingles and/or post herpetic neuralgia. 
Imunogeni pripravak ili cjepivo, koji sadrže glikoprotein E kao antigen iz virusa varicela-zoster (VZV) (gE), skraćen kako bi se uklonilo C-terminalno sidrišno područje, gdje skraćeniVZV gE nije u obliku fuzijskog proteina, u kombinaciji s adjuvansom TH-1, koji sadrži QS21 i 3D MPL, naznačeni time što su namijenjeni upotrebi u sprječavanju ili ublažavanju zone i/ili postherpetične neuralgije.
A kit comprising as separate components, the TH-1 adjuvant and the VZV gE antigen as defined for claim 1 or claim 2, suitable for extemporaneous preparation of a vaccine composition, for use in the prevention or amelioration of shingles and/or post herpetic neuralgia. 
Komplet koji kao odvojene komponente sadrži adjuvans TH-1 i antigen VZV gE u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je pogodan za improviziranu priprava cjepivnog pripravka, namijenjenog upotrebi u sprječavanju ili ublažavanju zone i/ili postherpetične neuralgije.
A kit for use according to claim 6 wherein the VZV gE antigen or immunogenic fragment thereof is for reconstitution in a solution containing the adjuvant before delivery. 
Komplet namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je antigen VZV gE, ili njegov imunogeni fragment, namijenjen rekonstituiranju u otopini koja sadrži adjuvans prije unosa.
A VZV gE antigen truncated to remove the C-terminal anchor region and not in the form of a fusion protein for use in the prevention or amelioration of shingles and/or post herpetic neuralgia, wherein the VZV gE antigen is to be administered in combination with a TH-1 adjuvant comprising QS21 and 3D MPL. 
Antigen VZV gE, skraćen kako bi se uklonilo C-terminalno sidrišno područje i koji nije u obliku fuzijskog proteina, namijenjen upotrebi u sprječavanju ili ublažavanju zone i/ili postherpetične neuralgije, naznačen time što antigen VZV gE treba primijeniti u kombinaciji s adjuvansom TH-1, koji sadrži QS21 i 3D MPL.
A computerized method of optimizing audio quality in a voice stream between a sender and a receiver VoIP applications, comprising: 
Kompjutorizirana metoda optimizacije kvalitete zvuka u glasovnom stream između pošiljatelja I prijemnika VOIP aplikacije koje uključuju:
The method of claim 1, wherein said determining (140) whether congestion exists comprises determining that congestion exists if the calculated one-way-delay is greater than a predefined positive constant or the calculated trend is greater than a predefined positive constant. 
Postupak sukladno patentnom zahtjevu 1, naznačen time što navedeno određivanje (140) postoji li zagušenje obuhvaća određivanje da zagušenje postoji ako je izračunato jednosmjerno odlaganje veće od unapred definirane pozitivne konstante ili je izračunati trend veći od unaprijed definirane pozitivne konstante.
The method of claim 2, further comprising determining congestion level based on said calculated trend value. 
Postupak sukladno patentnom zahtjevu 2, još obuhvaća određivanje razine zagušenja temeljem navedene izračunate vrijednosti trenda.
if there is no congestion setting (220) the bandwidth estimate as greater than the estimated incoming bitrate; and 
ako ne postoji postavka (220) zagušenja procjena propusnog obujma kao većeg od procjenjene dolazne brzine protoka; i
The dosage form for use according to any one of claims 1-3, wherein said solid solution or solid dispersion comprises at least one pharmaceutically acceptable water-soluble polymer is selected from the group consisting of homopolymers of N-vinyl lactam, copolymers of N-vinyl lactam, cellulose esters, cellulose ethers, high molecular polyalkylene oxides, polyacrylates, polymethacrylates, polyacrylamides, polyvinyl alcohol, vinyl acetate polymers, oligosaccharides, and polysaccharides, and wherein said solid solution or solid dispersion comprises at least one pharmaceutically acceptable surfactant having an HLB value of from 4 to 10 selected from the group consisting of polyoxyethylene alkyl ethers, polyoxyethylene alkylaryl ethers, polyethylene glycol fatty acid esters, alkylene glycol fatty acid mono esters, sucrose fatty acid esters, and sorbitan fatty acid mono esters. 
Oblik doziranja za uporabu prema zahtjevu 1, naznačen time da navedena otopina krutih tvari ili navedena disperzija krutih tvari sadrži barem jedan farmaceutski prihvatljiv polimer koji je topljiv u vodi odabran iz skupine koja sadrži homopolimer N-vinil laktama, kopolimer N-vinil laktama, celuloza ester, celuloza eter, visoko molekularni polialkilen oksid, poliakrilat, polimetakrilat, poliakrilamid, polivinil alkohol, vinil acetat polimer, oligosaharid, te polisaharid, te pri čemu navedena kruta otopina ili kruta disperzija sadrži barem jedan farmaceutski prihvatljiv surfaktant koji ima HLB vrijednost od 4 do 10 odabran iz skupine koja sadrži polioksietilen alkil eter, polioksietilen alkilaril eter, polietilen glikol ester masne kiseline, alkilen glikol mono ester masne kiseline, saharoza ester masne kiseline, te sorbitan mono ester masne kiseline.
The aqueous formulation of claim 1, comprising an analogue of exendin-4 selected from the group consisting of lixisenatide, exenatide and liraglutide. 
Vodena farmaceutska formulacija prema zahtjevu 1 naznačena time da sadrži analog eksendina-4 odabran iz skupine koja sadrži liksisenatid, eksenatid i liraglutid.
A heat exchanger panel system according to claims 1-2, characterised in that the height of a projection (18) and the upper surface (9) of the heat spreader sheet (3) provide an angle V of 2-45 degrees. 
Sustav pločastog izmjenjivača topline prema zahtjevu 1, naznačen time da visina izbočine (18) i gornje površine (9) ploče za raspršivanje topline (3) tvore kut V od 2-45 stupnjeva.
A heat exchanger panel system according to claims 1-4, characterised in that the longitudinal sides delimiting the aperture (16) of the recess (14) comprise nose-shaped protrusions (21). 
Sustav pločastog izmjenjivača topline prema zahtjevima 1-4, naznačen time da su uzdužne stranice koje razgraničavaju otvor (16) udubljenja (14) sadrže izbočine u obliku nosa (21).
A heat exchanger panel system according to claims 1, characterised in that the heat spreader sheet (3) is formed from a metal plate. 
Sustav pločastog izmjenjivača topline prema zahtjevu 1, naznačen time da je ploča za raspršivanje topline (3) izrađena od metalne ploče.
The system of claim 3 or 4, characterised in that the groove (6) fashioned at the rear end (2P) of the threaded tie-rod (2) comprises: 
Sustav u skladu s patentnim zahtjevom 3 ili 4, naznačen time što utor (6), načinjen na stražnjem kraju (2P) vučne šipke s navojem (2), ima:
an activating trigger; 
– aktivirajući okidač;
an oil-dynamic system comprising an oil-dynamic fluid, a cylinder, internally of which a piston slides, and activating means destined, by the action of the oil-dynamic fluid, to axially translate the threaded tie-rod in such a way as to determine a plastic deformation of a predetermined portion of the fixing element so as to block the fixing element to a corresponding wall; 
– uljno-dinamički sustav, koji sadrži uljno-dinamički fluid, cilindar, u čiju unutrašnjost ulazi klip, i aktivirajući element, koji, djelovanjem uljno-dinamičkog fluida, dovodi do aksijalnog pomicanja vučne šipke s navojem na takav način da odredi plastičnu deformaciju zadanog dijela elementa za pričvršćivanje, tako da blokira element za pričvršćivanje na odgovarajući zid;
a second electric micromotor able to set the threaded tie-rod (2) in rotation so as to engage or disengage the threaded tie-rod (2) to or from the threaded axial hole of the fixing element; 
– drugi električni mikromotor, koji može zavrtjeti vučnu šipku s navojem (2), tako da spoji ili odvoji vučnu šipku s navojem (2) s ili od aksijalne rupe s navojem elementa za pričvršćivanje;
at least an electronic control unit able to control and command the first and second electric micromotors; 
– u najmanju ruku elektroničku upravljačku jedinicu, koja može kontrolirati i upravljati prvim i drugim električnim mikromotorom;
a system for coupling/decoupling the threaded tie-rod 2 to and from the tie-rod seating (3) according to one of claims from 1 to 7. 
– sustav za spajanje/odvajanje vučne šipke s navojem (2) sa i od sjedišta vučne šipke (3) u skladu s bilo kojim od patentnih zahtjeva od 1 do 7.
a source of compressed air; 
– izvor stlačenog zraka;
Compound according to claim 1 or a salt thereof for use in a method of preventing or treating diabetes in a mammal, comprising administering an effective amount of the compound or salt thereof to the mammal. 
Spoj prema zahtjevu 1, ili njegova sol, naznačen/a time, da se upotrebljava u postupku prevencije ili liječenja dijabetesa kod sisavaca, pri čemu postupak obuhvaća davanje sisavcu učinkovite količine spoja ili njegove soli.
A heat exchanger panel system according to claim 1, characterised in that the height of a projection (18) and the upper surface (9) of the heat spreader sheet (3) provide an angle V of 2-45 degrees. 
Sustav pločastog izmjenjivača topline prema zahtjevu 1, naznačen time da visina izbočine (18) i gornje površine (9) ploče za raspršivanje topline (3) tvore kut V od 2-45 stupnjeva.
A process for preparing a compound of general formula (I) which comprise either: 
Postupak za pripremu spoja opće formule (I) koji sadrži ili:
reacting a compound of general formula (II) with an alcohol of the general formula R6-OH, or a salt thereof, 
reakciju spoja opće formule (II) s alkoholom opće formule R6-OH, ili njegovom soli,
wherein: LG represents a leaving group; 
gdje: LG predstavlja odlazeću grupu;
is hydrogen, halogen, cyano, nitro, alkylcarbonyl, formyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, or optionally halogen-substituted alkyl, aryl, alkoxy, alkylthio, alkylsulphinyl or alkylsulponyl, or one of the following radicals: wherein * denotes the point of attachment to the phenyl radical of formula (I); 
je vodik, halogen, cijano, nitro, alkilkarbonil, formil, alkoksikarbonil, aminokarbonil, alkilaminokarbonil, dialkilaminokarbonil ili izborno halogenom-supstituirani alkil, aril, alkoksi, alkiltio, alkilsulfinil ili alkilsulfonil, ili jedan od sljedećih radikala: gdje * označava točku vezivanja za fenil radikal formule (I);
is substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl, or a salt thereof; 
je supstituirani ili nesupstituirani aril, ili supstituirani ili nesupstituirani heterociklil, ili njegova sol;
with the proviso that R6 and the radical: are different from each other. 
uz uvjet da su R6 i radikal: međusobno različiti.
A process according to claim 1, wherein the catalyst is chosen among one or more of the following compounds: 1,4-diazabicyclo[2.2.2]octane (DABCO), N-methyl-pyrrolidine, N-methylpiperidine, N-methylmorpholine, hexamethylenetetramine, 1,4-diazabicyclo[2.1.1]hexane, quinuclidine, 3-quinuclidinol or 3-quinuclidinone. 
Postupak prema patentnom zahtjevu 1, naznačen time što je katalizator izabran od jednog ili više sljedećih spojeva: 1,4-diazabiciklo[2.2.2]oktan (DABCO), N-metil-pirolidin, N-metilpiperidin, N-metilmorfolin, heksametilentetramin, 1,4-diazabiciklo[2.1.1]heksan, hinuklidin, 3-hinuklidinol ili 3-hinuklidinon.
A process according to claim 3, wherein R1, R2, R3 and R4 are, independently, hydrogen or methyl. 
Postupak prema patentnom zahtjevu 3, naznačen time što su R1, R2, R3 i R4, nezavisno, vodik ili metil.
Cl-6, straight-chain or branched, halogenoalkyl, halogenoalkoxy, halogeno-alkylthio, halogenoalkylsulphinyl or halogenoalkylsulphonyl with between 1 and 13 identical or different halogen atoms; 
C1-6, ravnolančani ili razgranati, halogenoalkil, halogenoalkoksi, halogeno-alkiltio, halogenoalkilsulfinil ili halogenoalkilsulfonil s između 1 i 13 identičnih ili različitih atoma halogena;
the radical in which: 
radikal u kojem:
represents hydroxyl, methoxy, ethoxy, amino, methylamino, phenyl or benzyl; or represents Cl-4 alkyl or alkoxy, optionally substituted with cyano-, alkoxy-, alkylthio-, alkylamino-, dialkylamino- or phenyl; or represents C2-4 alkenyloxy or alkynyloxy; or represents benzoyl, benzoylethenyl, cinnamoyl, heterocyclyl; or represents phenylalkyl, phenylalkyloxy or heterocyclylalkyl, having in each case 1 to 3 carbon atoms in the alkyl moieties and being in each case optionally mono- to tri-substituted in the ring moiety by halogen and/or straight-chain or branched Cl-4 alkyl or alkoxy. 
predstavlja hidroksil, metoksi, etoksi, amino, metilamino, fenil ili benzil; ili predstavlja C1-4 alkil ili alkoksi, izborno supstituiran s cijano-, alkoksi-, alkiltio-, alkilamino-, dialkilamino- ili fenil; ili predstavlja C2-4 alkeniloksi ili alkinilioksi; ili predstavlja benzoil, benzoiletenil, cinamoil, heterociklil; ili predstavlja fenilalkil, fenilalkiloksi ili heterociklilalkil, koji ima u svakom slučaju 1 do 3 atoma ugljika u alkil grupama i koji je u svakom slučaju izborno mono- do trisupstituiran u grupi prstena s halogenom i/ili ravnolančanim ili razgranatim C1-4 alkilom ili alkoksi.
A process according to claim 1 for preparing the compound of formula (Ia) 
Postupak prema patentnom zahtjevu 1 za pripremu spoja formule (Ia)
A process according to claim 1 for preparing the compound of formula (Ib) 
Postupak prema patentnom zahtjevu 1 za pripremu spoja formule (Ib)
A process according to claim 1 for preparing the compound of formula (Id) 
Postupak prema patentnom zahtjevu 1 za pripremu spoja formule (Id)
The injection of claim 3, wherein the injection is consisted of (by weight): 1∼20 parts of 5a-androstane-3β,5,6β-triol, 40∼500 parts of hydroxypropyl-β-cyclodextrin, 1∼100 parts of an isotonic adjusting agent, 0∼200 parts of a freeze drying filler, and 0∼2000 parts of a solvent. A method for preparing the injection of claim 1, comprising steps of 
Injekcija prema patentnom zahtjevu 3, gdje se injekcija sastoji od (po masi): 1~20 dijelova 5a-androstan-3β,5,6β-triola, 40~500 dijelova hidroksipropil-β-ciklodekstrina, 1~100 dijelova izotoničnog sredstva za prilagodbu, 0~200 dijelova punila za ledeno sušenje, te 0~2000 dijelova otapala.
The formulation of claim 1, wherein the zinc chelator is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), EGTA, trisodium citrate (TSC), alginic acid, alpha lipoic acid, dimercaptosuccinic acid (DMSA) and CDTA (1,2-diaminocyclohexanetetraacetic acid). 
Formulacija prema zahtjevu 1, naznačena time da se navedeni kelator cinka bira iz skupine koju čine etilendiamintetraoctena kiselina (EDTA), EGTA, trinatrijev citrat (TSC), alginska kiselina, alfa lipoinska kiselina, dimerkaptojantarna kiselina (DMSA) i CDTA (1,2-diaminocikloheksantetraoctena kiselina).
The formulation of claim 5, wherein the zinc chelator is ethylenediaminetetraacetic acid (EDTA). 
Formulacija prema zahtjevu 5, naznačena time da je kelator cinka etilendiamintetraoctena kiselina (EDTA).
The formulation of claim 1, wherein the dissolution agent is an acid selected from the group consisting of acetic acid, ascorbic acid, citric acid, glutamic, succinic, aspartic, maleic, fumaric, and adipic acid, or a salt thereof, preferably citric acid or sodium citrate or a salt selected from the group consisting of acetate, ascorbate, citrate, glutamate, aspartate, succinate fumarate, maleate, and adipate and a metal Group I group II metal, preferably sodium or potassium ascorbate, citrate, glutamate, aspartate, succinate, fumarate, maleate, and adipate. 
Formulacija prema zahtjevu 1, naznačena time da je sredstvo za otapanje kiselina koja je odabran iz skupine koju čine octena kiselina, askorbinska kiselina, limunska kiselina, glutaminska kiselina, jantarna kiselina, aspartamska kiselina, maleinska kiselina, fumarna kiselina, i adipinska kiselina, ili njihove soli, poželjno limunske kiseline ili natrijevog citrata ili soli koji se biraju iz skupine koju čine acetat, askorbat, citrat, glutamat, aspartat, sukcinat fumarat, maleat, i adipat i skupina I metala skupina II metala, poželjno natrijev ili kalijev askorbat, citrat, glutamat, aspartat, sukcinat, fumarat, maleat, i adipat.
The formulation of claim 1 wherein the insulin is provided in a dry powder in a first container and at least one of the zinc chelator and dissolution agent are provided in a second container containing a diluent. 
Formulacija prema zahtjevu 1, naznačena time da je inzulin osiguran u obliku suhog praha u prvom spremniku i najmanje jedan kelator cinka i sredstvo za rastvaranje su osigurani u drugom spremniku koji sadrži otapalo.
An injectable insulin formulation according to any one of the preceding claims comprising insulin and an effective amount of a dissolution agent and a zinc chelator for use in enhancing uptake and transport of the insulin through epithelial cells, as compared to insulin in combination with said zinc chelator and HCl, for the treatment of a diabetic individual. 
Formulacija inzulina koja je namijenjena za davanje injekcijom prema bilo kojim prethodnim zahtjevima koja sadrži inzulin i učinkovitu količinu sredstva za otapanje i kelatora cinka za upotrebu u poboljšanju preuzimanja i transporta inzulina kroz epitelne stanice, u usporedbi s inzulinom u kombinaciji s navedenim kelatorom cinka i HCl, za liječenje pojedinca koji ima dijabetes.
Shell (1) according to Claim 1, characterized in that the discs (11) are 0.58 mm thick, circular and made of steel, and in that the number of discs (11) is within the range 30 - 60. 
Granata (1) u skladu s patentnim zahtjevom 1, naznačena time da su diskovi (11) debljine 0.58 mm, kružni i izrađeni od čelika, te time da je broj diskova (11) unutar raspona 30 - 60.
Shell (1) according to any one of Claims 1 to 3, characterized in that the discs (11), following ejection of the shell base (5), can be divided into smaller disc parts via engraved kerfs on the discs (11). 
Granata (1) prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time da se diskovi (11), nakon izbacivanja osnovice granate (5), mogu podijeliti na manje dijelove diska pomoću ugraviranih usjeka na diskovima (11).
The vaccine of claim 2, wherein the antigen is of bacterial origin, viral origin or parasitic origin. The vaccine of claim 3, wherein 
Cjepivo u skladu s patentnim zahtjevom 2, naznačeno time što je antigen bakterijskog podrijetla, virusnog podrijetla ili parazitnog poidrijetla.
The vaccine of claim 1, wherein the amount of cholesterol relative to the amount of antigen is 0.1 to 50 fold greater by weight, 1 to 10 fold greater by weight or equal in weight to the antigen. 
Cjepivo u skladu s patentnim zahtjevom 1, naznačeno time što je količina kolesterola u odnosu na količinu antigena 0,1 do 50 puta veća, težinski, 1 do 10 puta veća, težinski, ili jednaka težini antigena.
The vaccine of claim 1, further comprising a pharmaceutical carrier. 
Cjepivo u skladu s patentnim zahtjevom 1, naznačeno time što dodatno sadrži farmaceutski nosač.
a plurality of fibers forming a fiber dispersion within the thermoplastic polymer body, the fibers having an average length of less than 15 mm and an average diameter of less than 50 micrometers; 
množina vlakana koja čine vlaknastu disperziju unutar polimernog tijela (20), vlakna imaju prosječnu dužinu od manje od 15 mm i prosječni promjer od manje od 50 mikrometara;
The method according to claim 19, wherein the disease or disorder is selected from the group consisting of schizophrenia, delusion disorders, movement disorders, anxiety disorder, obsessive-compulsive disorder, and cognitive function disorder. 
Spoj za upotrebu prema zahtjevu 14, naznačen time što je bolest ili poremećaj izabran iz skupina koja se sastoji od shizofrenije, halucinogenih poremećaja, poremećaja pokreta, tjeskobnih poremećaja, opsesivno-kompulsivnih poremećaja i poremećaja kognitivnih funkcija.
The monolithic radiant panel as claimed in claim 1, wherein the angle is selected from a range of 0 degrees to 90 degrees. 
Sustav s monolitnim radijativnim panelom u skladu s patentnim zahtjevom 1, naznačen time što kut se bira u rasponu od 0° do 90°.
The monolithic radiant panel as claimed in claim 1, wherein the angle is 90 degrees. 
Sustav s monolitnim radijativnim panelom u skladu s patentnim zahtjevom 1, naznačen time što je kut 90°.
The wire fence according to claim 1, wherein each of said joints are obtained by wrapping a transverse wire end portion around the respective intersecting wire line so as to form a hinge joint. 
Žičana ograda u skladu s patentnim zahtjevom 1, naznačena time što je svaki od navedenih spojeva dobiven omatanjem krajnjeg dijela poprečne žice oko odgovarajuće ukrižene linijske žice kako bi se dobilo zglobni spoj.
The wire fence according to claim 3, wherein the hinge joint (20, 16') of an interior wire line (12i) is formed with end portions of two intersecting transverse wires (14i-1, 14i) coming from respective adjacent line wires. 
Žičana ograda u skladu s patentnim zahtjevom 3, naznačena time što je zglobni spoj (20, 16’) unutarnje linijske žice (12i) načinjen s krajnjim dijelovima dvije ukrižene poprečne žice (14i-1, 14i) koji izlaze iz odgovarajućih susjednih linijskih žica.
The wire fence according to claim 4 or 5, wherein said two intersecting transverse wires (141, 142) are wrapped in a helicoidal manner around said interior line wire (142), with one or more loops in common. 
Žičana ograda u skladu s patentnim zahtjevom 4 ili 5, naznačena time što su navedene dvije ukrižene poprečne žice (141, 142) omotane u obliku zavojnice oko navedene unutarnje linijske žice (142), s jednom ili više zajedničkih petlji.